AHA Scientific Sessions 2024 Late-Breaking and Featured Science Collection
Published: 29 October 2024
-
Views:
2109
-
Likes:
7
-
Views:
2109
-
Likes:
7
-
Up Next -
3m 49s -
5m 28sPart 3 | Session 11 ALPACAR: Phase 2 Trial of Zerlasiran in High Risk Patients -
3m 44sPart 3 | Session 12 BROOKLYN: Safety and Efficacy of Obicetrapib in Patients with HeFH -
3m 40sPart 3 | Session 13 KRAKEN: Phase 2 Trial of Muvalaplin in High Risk Patients -
5m 15sPart 3 | Session 14 OPTION: LAA Closure with Oral Anticoagulation after AF Ablation
-
13m 43sPart 1 View from the Thoraxcenter: AHA 24 Late-breaking Preview Joost Daemen, Nicolas M Van Mieghem
-
29m 32sPart 2 | Session 1 ZODIAC: Decision Support System to Aid Optimization of Early Lipid Lowering Therapies After ACS Harriette Van Spall, Kausik Ray
-
18m 41sPart 2 | Session 2 NUDGE-FLU: Electronic Nudges to Increase Influenza Vaccination in Patients with MI Harriette Van Spall, Tor Biering-Sørensen
-
17m 22sPart 2 | Session 3 SUMMIT: Tirzepatide in Patients with HFpEF and Obesity Harriette Van Spall, Milton Packer
-
16m 57sPart 2 | Session 4 FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk Harriette Van Spall, Katherine Tuttle
-
22m 30sPart 2 | Session 5 REALIZE-K: Efficacy and Safety of SZC in Patients with HFrEF Receiving Spironolactone Harriette Van Spall, Mikhail Kosiborod
-
6m 17sPart 3 | Session 1 LIBerate-OLE: Long-Term Efficacy of Lerodalcibep in Patients at High Risk for CVD Dean J Kereiakes
-
3m 53sPart 3 | Session 2 LIBerate-HeFH_OLE: Lerodalcibep in Heterozygous Familial Hypercholesterolemia Frederick Raal
-
7m 19sPart 3 | Session 3 Mavacamten: Real-World Experience from 22 Months of the REMS Program Milind Y Desai
-
10m 31sPart 3 | Session 4 VALOR-HCM: Mavacamten in Patients with Obstructive HCM Referred for Septal Reduction Therapy Milind Y Desai
-
4m 41sPart 3 | Session 5 EMPEROR-Preserved: Diastolic Dysfunction and Empagliflozin in Heart Failure Andrew JS Coats
-
6m 53sPart 3 | Session 6 Amulet IDE: The AMPLATZER Amulet Left Atrial Appendage Occluder Five-Year Results Dhanunjaya Lakkireddy
-
5m 6sPart 3 | Session 7 NTLA-2001 in Patients with Transthyretin Amyloidosis with Cardiomyopathy Marianna Fontana
-
5m 7sPart 3 | Session 8 SELECT: Semaglutide in Obese and Overweight Patients with a History of Coronary Artery Bypass Surgery Subodh Verma
Overview
Keep up-to-date with our video collection covering the American Heart Association's 2024 Scientific Sessions in Chicago. For expert insights on the hottest late-breaking and featured science trials, tune in to our collection.
- To catch reviews on the most awaited trials, watch our recurring series View From the ThoraxCenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
- Watch out for the Late-Breaker Discussions with Dr Harriette Van Spall for key clinical trial data and its implications for future research.
- Our concise Expert Interviews provide key data, study designs and take-home messages from select faculty.
- Don't miss the key take aways from our Highlights series.
More from this programme
Part 1
View From the Thoraxcenter
Part 2
Late-Breaker Discussions with Dr Harriette Van Spall
Part 3
Expert Interviews
Part 4
Highlights
About the episode
AHA Conference 2024 - Primary safety and efficacy results from ENDEAVOR investigating the effect of myeloperoxidase inhibition with mitiperstat (AstraZeneca) on symptoms and exercise capacity in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).
Dr Sanjiv Shah (Bluhm Cardiovascular Institute, Chicago, US) joins us onsite at AHA Conference to discuss the findings from ENDEAVOR (NCT04986202).
ENDEAVOR is double-blind, randomized, placebo-controlled, phase 2b and phase 3 trial investigating the use of mitiperstat in patients with HFpEF and HFmrEF. 709 patients were randomized 1:1:1 to receive either mitiperstat 2.5 mg, 5 mg or placebo. Patients were followed-up from baseline to week 16 and week 24, and the primary outcome measures were the change from baseline of Kansas City Cardiomyopathy Questionnaire Total Symptom Score and six minute walk distance.
Interview Questions:
1. What is the importance behind the ENDEAVOR trial?
2. Could you tell us about the mechanism of action behind mitiperstat?
3. What was the study design and patient population?
4. What were the key findings?
5. What further research is needed in this area?
Recorded on-site at AHA Conference in Chicago, 2024.
Editors: Yazmin Sadik, Jordan Rance.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.
Support: This is an independent interview produced by Radcliffe Cardiology.
Faculty Biographies
Sanjiv Shah
Professor
Dr Sanjiv Shah’s clinical expertise and research program are focused on HFpEF and in 2007, Dr Shah started the first dedicated HFpEF program in the world at Northwestern University.
His research, which spans basic research in animal models, clinical physiologic studies, human clinical trials, and population-based epidemiology studies, has highlighted the heterogeneity and systemic nature of the HFpEF syndrome, and has improved the understanding of the risk factors, pathogenesis, and pathophysiology of HFpEF.
He is an internationally recognised leading authority on HFpEF and routinely lectures at international cardiology meetings, continuing medical education meetings, and academic institutions.
Comments